Physion

Physion is a specialized biotechnology platform company that provides advanced physiological simulation software and services for drug discovery and safety pharmacology. The company’s core technology enables the in silico prediction of drug-induced effects on cardiac function, particularly focused on identifying potential pro-arrhythmic risks. By utilizing high-fidelity computational models of human heart cells and tissues, Physion allows pharmaceutical companies to assess the safety profiles of small molecule candidates early in the development process. Their flagship PhySio-Plus platform is designed to reduce the reliance on animal testing while improving the clinical success rates of new therapeutics. Physion operates as a key collaborator for major pharmaceutical firms, helping to streamline the evaluation of ion channel interactions and cardiac toxicity.